Auspherix Pty Ltd, an early-stage anti-infectives company spun out from UTS's ithree institute, has secured an additional $1million from the MRCF, doubling the fund's initial support.
In less than 12 months since its foundation, Auspherix has identified a number of novel antibacterial compounds with potential to act against a range of resistant bacteria.
Auspherix founder and Chief Scientific Officer, and Director of the ithree institute, Professor Ian Charles, said that in a short time the research team had developed a better understanding of what was necessary to target the organisms and had improved the antibiotic activity of the initial compounds.
The MRCF investment will allow Auspherix to progress its antibacterial compounds through development studies.
Read the full article online on UTS:Newsroom